Carrier Screening Market

Carrier Screening Market Overview

The global carrier screening market size, valued at USD 2.1 billion in 2024, is projected to reach USD 2.43 billion in 2025 and USD 7.51 billion by 2035, representing a CAGR of 11.9% during the forecast period.

To learn more about this report, request a free sample copy

Carrier screening is a form of genetic test that helps to determine whether an individual is carrying a gene for genetic disorder. This test is generally conducted before or during pregnancy to predict the chances of genetic disorders in baby. With growing concern of genetic disorders and chronic conditions across the globe, the healthcare industry has necessitated the carrier screening of prenatal and newborn.

It is worth mentioning that carrier screening helps in early detection of genetic disease risk so healthcare providers can provide necessary intervention, help individuals in family planning and avail necessary assisted reproductive technologies to reduce the chances of having an affected child. Considering the essentiality of carrier screening, industrial players are focusing on next generation screening technologies for faster results with higher accuracy rate. For instance, in June 2024, Myriad Genetics (a global leader in genetic testing and precision medicine) announced the addition of Universal Plus Panel to its Foresight^® Carrier Screen. This Universal Plus Panel includes 39 conditions and holds potential to screen up to 72 genes associated with inherited conditions.

Moreover, several government organizations and industrial players are focusing on strategic initiatives to enhance carrier screening of individuals to determine couples at greater risk of genetic conditions. For instance, KK Women’s and Children’s Hospital and Temasek Foundation conjointly launched Temasek Foundation PREDICT (Parenthood Genetic Disease Carrier Test) Programme, a first-in-Asia enhanced screening program for couples in Singapore seeking to conceive or who are already expecting. This program aims to detect if the couple have carriers of gene or recessive genetic disorder gene that may pass to the offspring.

These ongoing initiatives by industrial organizations are expected to drive the market at a steady rate during the forecast period, offering enormous opportunities for technological innovations.

Carrier Screening Market Segmentation Insights

The market report provides comprehensive information on industrial players who are currently active across various segments of the industry as mentioned in the table below.

Carrier Screening Market: Report Attributes / Market Segmentation

Key Report Attributes	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Market Size 2025	USD 2.43 Billion
Market Size 2035	USD 7.51 Billion
CAGR (Till 2035)	11.9%
Type of Carrier Screening	Expanded Carrier Screening Targeted Disease Carrier Screening
Type of Disease	Cystic Fibrosis Tay-Sachs Gaucher Disease Sickle Cell Disease Spinal Muscular Atrophy Other Diseases
Type of Medical Condition	Pulmonary Conditions Hematological Conditions Neurological Conditions Other Medical Conditions
Type of Technology	DNA Sequencing Polymerase Chain Reaction Microarrays Other Technologies
Application Area	Prenatal Screening Preconception Screening Newborn Screening
End-User	Hospitals, Laboratories Physician Offices & Clinics Other End-Users
Geographical Regions	North America (US, Canada and Mexico) Europe (France, Germany, Italy, Spain, UK and Rest of Europe) Asia Pacific (China, India, Japan, South Korea, and Rest of Asia Pacific) Middle East and North Africa (Egypt, Saudi Arabia and United Arab Emirates) Latin America (Argentina and Brazil)
Key Companies Profiled	Eurofins Scientific Fulgent Genetics Invitae Illumina Luminex Gene By Gene Mount Sinai Genomics MedGenome Myriad Genetics Natera Otogenetics Opko Health Sema4 OpCo Quest Diagnostics Thermo Fisher Scientific (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Available

One of the key objectives of the carrier screening market analysis was to estimate the current size, opportunity, and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.

The global market analysis report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of carrier screening (expanded carrier screening and targeted disease carrier screening), type of disease (cystic fibrosis, Tay-Sachs, Qaucher disease, sickle cell disease, spinal muscular atrophy and other medical conditions), type of medical condition (pulmonary conditions, hematological conditions, neurological conditions and other medical conditions), type of technology (DNA sequencing, polymerase chain reaction, microarrays and other technologies), application area (prenatal screening, preconception screening and newborn screening), end-user (hospitals, laboratories, physician offices & clinics and other end-users), geographical region (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) and leading players.

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three carrier screening market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.

Carrier Screening Market Share Insights

Market Share by Type of Carrier Screening

Based on the type of carrier screening, the global market is segmented into expanded carrier screening (customized panel testing and predesigned panel testing) and targeted disease carrier screening. According to our carrier screening market analysis, currently expanded carrier screening segment is dominating the market and is expected to hold nearly 65% share of the market by 2035.

This can be attributed to the fact that expanded carrier screening tests can screen large number of genetic conditions as compared to other tests. Moreover, the expanded carrier screening test can help to identify multiple potential risks for the conditions that are rare or do not have any family history.

Additionally, the availability of next generation sequencing technologies has made it possible to screen large number of screening. Owing to widespread usage, the expanded screening test segment is likely to register a higher CAGR during the forecast period.

Market Share by Type of Disease

The global market is segmented across different types of disease, such as cystic fibrosis, Tay Sachs, Gaucher disease, sickle cell disease, spinal muscular atrophy and other diseases. According to our market report, cystic fibrosis holds the highest carrier screening market share. This can be attributed to the fact that cystic fibrosis is a relatively common type of genetic disorder and has well-established carrier screening methodologies for early screening.

However, in the long run, spinal muscular atrophy may register a higher CAGR during the forecast period driven by the increasing awareness and high recommendation of healthcare professionals for routine screening of spinal muscular atrophy.

Market Share by Type of Medical Condition

Based on the type of medical condition, the global market is segmented into pulmonary conditions, hematological conditions, neurological conditions and other medical conditions. According to the report, currently the pulmonary conditions segment holds the largest carrier screening market share. This can be attributed to the fact that pulmonary diseases are prevalent globally including cystic fibrosis. Carrier screening thus helps in early detection and effective treatment planning to improve quality of life.

However, in the long run, hematological conditions segment is likely to grow at a higher CAGR during the forecast period. This is primarily due to the increasing concern of hematological conditions, such as anemia, sickle cell disease and bleeding disorder. Additionally, the growing focus on preventive treatment has further underscored the demand for advanced carrier screening tests.

Market Share by Type of Technology

Based on the type of technology, the global carrier screening market size is segmented into DNA sequencing, polymerase chain reaction, microarrays and other technologies. According to the market report, currently DNA sequencing is dominating the market by holding nearly 40% market share.

DNA sequencing technologies, such as next generation sequencing, single cell sequencing and whole genome sequencing play a significant role in the identification of wide range of genetic variations, making is an unprecedented tool for screening genetic conditions at earliest. Additionally, the growing shift towards personalized medicine has further bolstered the demand for DNA sequencing for detailed analysis of genes. Driven by the growing demand, this segment is likely to remain dominant, expecting to grow at a higher CAGR during the forecast period.

Market Share by Application Area

Based on the application area, the global market is distributed across, prenatal screening, preconception screening and newborn screening. According to our carrier screening market analysis, currently the prenatal screening segment holds the highest share of the market. This is primarily due to the increasing focus on identification of abnormalities / genetic conditions during pregnancy. Notably, prenatal screening helps to make an informed decision for early intervention by identifying the potential risk of inherited diseases.

However, newborn screening segment is likely registering a substantial CAGR during the forecast period. This is primarily due to the fact that newborn screening enable early detection of genetic conditions that may affect the health of an infant. Therefore, this screening test is essential to take preventive healthcare measures.

Market Share by End-User

The global market is further categorized across different end-users, such as hospitals, laboratories, physician offices & clinics and other end-users. Currently, the hospitals’ segment accounts for the largest share (nearly 50%) of the market forecast. This is likely to be the growing adoption of carrier screening technologies for early diagnosis and identification of genetic abnormalities during pregnancy.

However, in the long run, laboratories segment is likely to register a higher CAGR. This is potentially due to the growing expansion of laboratories, availability of advanced technologies and preferences for personalized diagnostics laboratories by the patients.

Market Share by Geographical Region

Based on the geographical region, the global carrier screening market size is distributed across North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our market report, currently North America accounts for the largest share (41%) of the market. This can be attributed to the increasing incidence of genetic disorders and rising demand for advanced prenatal testing and newborn screening technologies for the identification of genetic conditions. Moreover, the increasing technological innovations by industrial players, such as Pfizer and Thermo Fisher Scientific in this region has contributed to the highest share.

In Asia-Pacific, the market for carrier screening is expected to grow at a higher CAGR during the forecast period. This lucrative growth is due to the increasing initiatives by government organizations and healthcare providers to conduct carrier screening for pregnant women to identify the potential risk of genetic disorders. As per the study published in ResearchGate, nearly 100,000 patients in India are diagnosed with β-thalassemia syndrome. The growing concern of genetic disorders has necessitated the demand for carrier screening test, which is expected to be a key reason for lucrative growth.

Carrier Screening Market Dynamic Insights

The “Carrier Screening Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities for carrier screening test developers. The market research report lays emphasis on the carrier screening products that are being developed. Key takeaways of the market report are briefly discussed below.

Carrier Screening Market Competitive Landscape

The current market landscape of carrier screening is highly competitive, featuring the presence of well-established and new entrants. Majority of the industrial players are focusing on technological innovations for faster and accurate diagnostics.

Furthermore, the market players are undertaking strategic initiatives to strengthen their product portfolio and increase technological advancements. For instance, in October 2024, Myriad Genetics and jscreen™ entered into a strategic partnership to strengthen the Myriad’s high-quality hereditary cancer and reproductive genetics products, such as Foresight® Carrier Screen and MyRisk® with RiskScore®. Under this partnership, the jscreen program is intended to reach hundreds of thousands of high-risk adults in United States through different outreach, in-person genetic screenings and educational events.

With growing partnerships between industrial players, we believe that the carrier screening market is expected to remain competitive during the forecast period.

Carrier Screening Market Key Drivers: Increasing Initiatives for Early Detection and Rising Prevalence of Genetic Disease

The global market is driven by the increasing initiatives for early detection of chromosomal abnormalities. Additionally, the increasing concern of genetic diseases across the globe has further surged the demand for carrier screening test. It is worth mentioning that prenatal screening can help to identify abnormalities at early stage during pregnancy. Moreover, the growing awareness about carrier screening and its role in preventive measures is the key driver for the market.

Carrier Screening Market Key Challenges: Stringent Regulatory Framework and Lack of Skilled Personnel

Despite the high demand, several challenges that may hinder market progress include complex regulatory challenges and lack of skilled personnel. Notably, the lack of standardized guidelines for the approval and development of carrier screening technologies may create challenges for the industrial players. Additionally, lack of skilled personnel to perform carrier screening test, ethical concerns and reimbursement issues may restrict the market growth during the forecast period.

Carrier Screening Market Trends: Advancements in Next-Generation Sequencing (NGS) in Carrier Screening and Rising Demand for Genetic Counselling

Some of the potential market growth factors that are anticipated to propel the market include growing technological advancements in next generation sequencing technologies and increasing emphasis on genetic counselling. Currently, the industrial players are focusing on the technological revolution that enabled researchers to identify genetic abnormalities effectively. Moreover, the market players are greatly emphasizing on making carrier screening cost-effective to enhance its adoption rate globally, which is expected to be a key growth factor for the market.

Carrier Screening Market Size Analysis

According to our market analysis, the global market for carrier screening is valued estimated at USD 2.43 billion in 2025 and is poised to reach USD 7.51 billion by 2035, representing a CAGR of 11.9% during the forecast period. This unprecedented growth is primarily due to the growing initiative by the industrial players to develop advanced technologies.

For instance, in March 2024, The Prelude Network® (Prelude) announced the expansion of its partnership with Labcorp to serve as its preferable Genetic Carrier Screening Lab. As stated by TJ Farnsworth (Founder and Chief Executive Officer, Inception Fertility), “Genetic screening is a vital part of fertility diagnostics as it helps patients and physicians make critical decisions on care and treatment options that lead to optimal outcomes.”

Owing to the ongoing partnerships between industrial players, the market is expected to be competitive during the forecast period.

Leading Companies in Carrier Screening Market

Examples of key players engaged in this domain (which have also been captured in this report) include Eurofins Scientific, Fulgent Genetics, Invitae, Illumina, Luminex, Gene By Gene, Mount Sinai Genomics, MedGenome, Myriad Genetics, Natera, Otogenetics, Opko Health, Sema4 OpCo, Quest Diagnostics and Thermo Fisher Scientific.

Carrier Screening Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this domain across different segments. Amongst other elements, the market report includes:

• A preface providing an introduction to the full report, Carrier Screening Market, 2020-2024 (Historical Trends), and Future Forecast till 2035 (Forecasted Estimates).
• An outline of the systematic research methodology adopted to conduct the study on the market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure the accuracy and reliability of our findings.
• An overview of economic factors that impact the overall carrier screening market growth, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
• An executive summary of the insights captured during our research. It offers a high-level view of the current state of the carrier screening market size and its evolution in the mid-and long-term.
• A detailed assessment of the carrier screening companies landscape is based on several relevant parameters, including years of experience, company size, headquarters location, and ownership structure.
• Elaborated profiles of prominent players engaged in offering carrier screening products, featuring information on their year of establishment, location of headquarters, company size, company mission, company footprint, management team, contact details, financial information, operating business segments, carrier screening product portfolio, recent developments, and an informed future outlook.
• A discussion on affiliated trends, key drivers, and challenges under a SWOT framework, which is likely to impact the industry's evolution, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall carrier screening industry.
• A market impact analysis features a discussion on the factors that can impact the growth of the carrier screening market.
• A detailed estimate of the current market size and the future growth potential of the market over the next decade. Based on multiple parameters, we have provided an informed estimate of the market's evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunities within the carrier screening industry. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
• Detailed projections of the current and future market size across various types of carrier screening, including expanded carrier screening and targeted disease carrier screening.
• Detailed projections of the current and future market analysis across various types of disease, including cystic fibrosis, Tay-Sachs, Gaucher disease, sickle cell disease, spinal muscular atrophy and other medical conditions.
• Detailed projections of the current and future carrier screening industry size across various type of medical condition, including pulmonary conditions, hematological conditions, neurological conditions and other medical conditions.
• Detailed projections of the current and future carrier screening market size across various types of technology, including DNA sequencing, polymerase chain reaction, microarrays and other technologies.
• Detailed projections of the current and future opportunities for carrier screening companies across various application areas, including prenatal screening, preconception screening and newborn screening.
• Detailed projections of the current and future market size across various types of end-user, including hospitals, laboratories, physician offices & clinics and other end-users.
• Detailed projections of the current and future market for carrier screening across various key geographical regions, such as North America (US, Canada and Mexico), Europe (France, Germany, Italy, Spain, UK and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, and Rest of the Asia-Pacific), Middle East and North Africa (Egypt, Saudi Arabia and UAE), and Latin America (Argentina and Brazil).

Recent Developments in Carrier Screening Market

Several recent developments have taken place in the field of carrier screening. We have outlined some of these recent initiatives below.

• In March 2025, Bio-Techne announced that Asuragen (a Bio-Techne Brand) collaborated with Oxford Nanopore Technologies to launch latest AmplideX^® Nanopore Carrier Plus Kit. This new genetic panel and analysis software can aid in carrier screening research and resolve genes that are difficult to analyze by conventional short-read sequencing.
• In March 2025, NxGen MDx announced the launch of Total Insight Pregnancy Panel™, a groundbreaking solution that combines three essential testing tools, such as non-invasive prenatal testing, carrier screening and an advanced UTI panel. This advanced panel has been designed to offer unparalleled insight into fetal health, allowing healthcare providers to address microbiological and genetic disease risks.
• In November 2024, Asuragen, (a Bio-Techne brand) highlighted its latest research products for breast cancer monitoring and carrier screening at Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo.